Surmodics Reports Third Quarter of Fiscal Year 2025 Financial Results; Updates Fiscal Year 2025 Financial Guidance
SRDXEDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its third quarter ended June 30, 2025, and updated its financial guidance for the fiscal year ending September 30, 2025. Third Quarter Fiscal 2025 Financial Summary Total Revenue of $29.6 million, a decrease of 3% year-over-year Total Revenue excluding SurVeil™ drug-coated balloon (“DCB”)
Surmodics to Report Third Quarter of Fiscal 2025 Financial Results on August 8
SRDXEDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that third quarter of fiscal year 2025 financial results will be released before the market opens on Friday, August 8. Given the pending acquisition by GTCR, Surmodics will not be hosting a live webcast and conference call to discuss the third quarter of fiscal 2025 financial results and accomplishments. Abou
Needham Reiterates Hold on Surmodicsto Hold
SRDXSurmodics Sees FY2025 GAAP EPS $(1.60)-$(1.40) vs $(0.61) Est
SRDXSurmodics Sees FY2025 Adj EPS $(0.62)-$(0.42) vs $(0.37) Est; Sees Sales $114.000M-$117.000M vs $127.27M Est
SRDXSurmodics Q2 Adj. EPS $(0.13) Misses $(0.11) Estimate, Sales $28.09M Miss $32.23M Estimate
SRDXA Look at Surmodics's Upcoming Earnings Report
SRDXSurmodics Reveals Publication Of TRANSCEND Trial, Highlighting Drug-Delivery Technology Of Its SurVeil Drug-Coated Balloon
SRDXSurmodics Announced The Commercial Release Of The Pounce XL Thrombectomy System, The Latest In A Suite Of Pounce Thrombectomy Systems That Provide Rapid Endovascular Removal Of Acute Or Chronic Clot From Peripheral Arteries
SRDXLake Street Upgrades Surmodics to Buy, Maintains Price Target to $43
SRDXWhy Surmodics Stock Is Falling On Friday
SRDXSurmodics stock drops 4.76% in premarket trading following news that the FTC will challenge its proposed acquisition by GTCR.
Surmodics Vows to Fight FTC Lawsuit Blocking $627M Acquisition by GTCR
SRDXSurmodics Q4 2024 Adj EPS $(0.13) Beats $(0.29) Estimate, Sales $33.23M Beat $30.40M Estimate
SRDXLooking Into Surmodics's Return On Capital Employed
SRDXSurmodics (NASDAQ:SRDX) brought in sales totaling $26.11 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 45.2%, resulting in a loss of $4.08 million.
Needham Maintains Buy on Surmodics, Lowers Price Target to $46
SRDX